Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

Lux Biosciences GmbH

Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company’s business strategy is characterized by:
• A focus on compounds already marketed or with clinical proof-of-concept in non-ophthalmic indications that Lux will develop as unique, targeted therapies for corresponding ophthalmic diseases, with potentially greater efficacy and safety than existing treatments.
• A clinical and preclinical stage portfolio of projects including a next-generation calcineurin inhibitor with potential in several ophthalmic diseases and, as such, represents a pipeline of product opportunities. Lux plans to begin pivotal clinical testing for the first indication by early 2007 and – if successful – this product will reach the market in 2009.
This strategy is being implemented by an experienced, execution-oriented management team that combines a history of achievement in drug development and commercialization with deep insight and scientific expertise in the fields of immunology and ophthalmology.


Lux Biosciences GmbH

Rubensstr. 14
60596 Frankfurt am Main
Forschung & Lehre